Focus shifts to broader immune targeting
Drug development in inflammatory skin disease is moving beyond single-target biologic therapies, according to Christopher Bunick, MD, PhD. In remarks highlighted by Dermatology Times, Bunick pointed to a growing effort to expand the immune pathways targeted by advanced biologic medicines.
The approach centres on medicines designed to act on more than one target at the same time. These are commonly described as bispecific (two targets) or trispecific (three targets) biologics.
What bispecific and trispecific biologics are designed to do
Bunick said these multi-target biologics are being developed with a goal of achieving deeper skin clearance and more meaningful relief from symptoms. In inflammatory skin disorders, patients can face persistent signs and symptoms that affect daily comfort, sleep, and quality of life.
By engaging multiple inflammatory drivers simultaneously, developers aim to improve treatment outcomes compared with therapies that focus on a single immune pathway.
Development pipeline highlights next phase of treatment
The Dermatology Times report described these medicines as being in development, indicating an active pipeline rather than established, routine clinical use. The emphasis is on expanding therapeutic targets—an approach that reflects how understanding of inflammatory mechanisms in skin disease continues to evolve.
While the underlying concept is multi-pathway suppression or modulation, the stated objectives remain practical for patients: clearer skin and improved symptom control.
Why the target expansion matters
The discussion reflects a broader trend in immunology-driven medicine, where newer therapies attempt to address complex inflammatory networks. In skin disease, targeting multiple pathways may be explored as a way to deliver stronger and more durable responses for individuals who do not reach desired clearance or relief with existing options.
Bunick’s comments underline that biologic therapy development is not limited to refining current targets but also includes creating medicines designed to intervene at several points in the inflammatory process.